Researchers from Utah found that PET/CT is far superior to SPECT for diagnosing myocardial ischemia, with higher sensitivity at a lower radiation dose, according to a paper presented on Sunday at the American College of Cardiology (ACC) meeting in San Diego. PET/CT in particular far outstripped SPECT in determining that patients were free of cardiac disease. {read more here}

The National Oncologic PET Registry (NOPR) Working Group submitted a formal request to the Centers for Medicare and Medicaid Services (CMS), to end the prospective data collection requirements under Coverage with Evidence Development (CED) for use of NaF-18 PET (CAG-00065R) imaging in intended patient management. CMS has initiated its review of this request. {read more here}

Researchers from Utah found that PET/CT is far superior to SPECT for diagnosing myocardial ischemia, with higher sensitivity at a lower radiation dose, according to a paper presented on Sunday at the American College of Cardiology (ACC) meeting in San Diego. PET/CT in particular far outstripped SPECT in determining that patients were free of cardiac disease. {read more here}

Amyloid imaging can tell Alzheimer’s disease (AD) and frontotemporal dementia (FTD) apart because FTD typically does not show the same pattern of amyloid, right? Not so fast, say brain researchers.

Amyvid, a F-18 florbetapir injection, was first FDA approved in April, 2012, and made a big splash in amyloid imaging as a diagnostic aid for AD. It is well understood by now that the agent does not diagnose AD, but the absence of amyloid deposition is a green light for ruling out the disease. Alzheimer’s disease is not the only form of dementia being investigated with brain PET. It just so happens that FTD can also present patterns of amyloid deposition—although significantly less so. Researchers hoped that F-18 florbetapir would be helpful for discerning one dementia from the next, but it turns out that it is a little more complicated than that. {read more here}